Johnson & Johnson (JNJ – Q4FY19 & FY19) – Q4 reflected continued operational sales and earnings growth.

in , on March 16, 2020

J&J has strong pipeline of products which will continue to deliver growing sales to keep revenue from its
pharmaceuticals segment afloat. Some of the company’s current products are also seeking additional indications. Imbruvica is currently in phase 3 testing for the treatment of mantle cell lymphoma, and Tremfya is in phase 3 testing for the treatment of pediatric psoriasis. It also gained FDA approval for two new drugs in 2019, Balversa and Spravato.

Executive Summary

Financial Statements

–Income Statement and Forecast
–Balance Sheet
–Cash Flow
–Q4FY19 Results Overview
–FY19 Results Overview
–Q4FY19 Segment Performance
–Q4FY19 Developments
–FY19 Guidance
–Conclusion
–GAAP to Non GAAP Reconciliation

Historical Performance
–Key Ratios
–Profitability Ratios, Asset Turnover Ratio, Growth Ratio
–DuPont Analysis
–Return on Invested Capital
–Per Share Items and Key Ratios
–Key Balance Sheet Items and Cash Flow Items
–P/E Band

Product Performance and Key Developments

–Ownership
–Competitors
–Key Developments

Valuation and Consensus Performance

–Relative Valuation
–Analyst Recommendations

Market Price Performance 

Release Information

  • Released
    :

    March 16, 2020

  • Last Updated
    :

    March 18, 2020